BioMarin Pharmaceutical Inc.
General ticker "BMRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.8B (TTM average)
BioMarin Pharmaceutical Inc. does not follow the US Stock Market performance with the rate: -2.5%.
Estimated limits based on current volatility of 1.2%: low 54.65$, high 55.93$
Factors to consider:
- Total employees count: 3221 (+6.0%) as of 2025
- Top business risk factors: Strategic risks and growth management, Economic downturns and volatility, Regulatory and compliance, Litigation risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [42.83$, 68.82$]
- 2026-12-31 to 2027-12-31 estimated range: [47.00$, 73.89$]
Financial Metrics affecting the BMRN estimates:
- Negative: with PPE of 23.8 at the end of fiscal year the price was high
- Positive: 6.59 < Operating cash flow per share per price, % of 7.39
- Positive: 7.54 < Operating profit margin, % of 12.71
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 4.39
- Positive: Inventory ratio change, % of -1.33 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 80.16 > 64.29
- Negative: Industry earnings per price (median), % of -13.66 <= 0
Short-term BMRN quotes
Long-term BMRN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,419.23MM | $2,863.91MM | $3,221.25MM |
| Operating Expenses | $2,233.45MM | $2,379.70MM | $2,811.78MM |
| Operating Income | $185.77MM | $484.21MM | $409.48MM |
| Non-Operating Income | $2.79MM | $57.55MM | $73.00MM |
| Interest Expense | $17.34MM | $12.67MM | $10.90MM |
| R&D Expense | $746.77MM | $747.18MM | $921.93MM |
| Income(Loss) | $188.56MM | $541.76MM | $482.48MM |
| Taxes | $20.92MM | $114.90MM | $133.58MM |
| Net Income(Loss)* | $167.65MM | $426.86MM | $348.90MM |
| Stockholders Equity | $4,951.55MM | $5,657.99MM | $6,087.00MM |
| Inventory | $1,107.18MM | $1,232.65MM | $1,298.88MM |
| Assets | $6,841.60MM | $6,988.94MM | $7,594.02MM |
| Operating Cash Flow | $159.26MM | $572.84MM | $827.99MM |
| Capital expenditure | $96.69MM | $97.42MM | $103.04MM |
| Investing Cash Flow | $-111.24MM | $136.49MM | $-414.24MM |
| Financing Cash Flow | $-18.73MM | $-526.45MM | $-42.39MM |
| Earnings Per Share** | $0.89 | $2.25 | $1.82 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.